185428-18-6
Chemical Structure
Rivoglitazone
Synonym(s): R-106056
- CAS No.: 185428-18-6
- Formula:C20H19N3O4S
- Molecular Weight:397.45
IUPAC Name: 5-(4-((6-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)benzyl)thiazolidine-2,4-dione
InChIKey: XMSXOLDPMGMWTH-UHFFFAOYSA-N
SMILES: O=C(N1)SC(CC2=CC=C(OCC3=NC4=CC=C(OC)C=C4N3C)C=C2)C1=O
Biological Activity: Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC50 of 0.22 μM for hPPARγ. Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A1C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rivoglitazone | 98.59% | Rivoglitazone (R-106056) is an orally active, selective PPARγ agonist with an EC50 of 0.22 μM for hPPARγ. Rivoglitazone regulates fatty acid storage and uptake, glucose homeostasis, and cardiac glucose/fatty acid metabolism. Rivoglitazone reduces levels of hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, decreases hepatic glucose production, and accelerates plasma triglyceride clearance. Rivoglitazone induces a reduction in glycated hemoglobin A1C, while causing peripheral edema and weight gain. Rivoglitazone can be used in research related to type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rivoglitazone (Standard) | ≥98% | Rivoglitazone (Standard) is the analytical standard of Rivoglitazone (HY-106181). This product is intended for research and analytical applications. Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the research of type 2 diabetes mellitus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Koffarnus RL, et al. Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2013;47(6):877-885. [Content Brief]
- [2]. Pfanzagl B, et al. The Transient Receptor Potential Vanilloid 4 Agonist RN-1747 Inhibits the Calcium Response to Histamine. Pharmacology. 2019;104(3-4):166-172. [Content Brief]
- [3]. Kanda S, et al. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models. J Pharmacol Sci. 2009;111(2):155-166. [Content Brief]
- [4]. Uchiyama M, et al. Pharmacokinetics, metabolism, and disposition of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys. Drug Metab Dispos. 2011;39(4):653-666. [Content Brief]
